Equities research analysts expect Crispr Therapeutics AG (NASDAQ:CRSP) to announce $59.43 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Crispr Therapeutics’ earnings, with the highest sales estimate coming in at $76.70 million and the lowest estimate coming in at $14.30 million. Crispr Therapeutics reported sales of $120,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 49,425%. The company is scheduled to announce its next earnings results on Monday, February 24th.
According to Zacks, analysts expect that Crispr Therapeutics will report full year sales of $272.00 million for the current financial year, with estimates ranging from $226.90 million to $289.27 million. For the next fiscal year, analysts anticipate that the business will report sales of $30.04 million, with estimates ranging from $2.03 million to $58.10 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%.
CRSP has been the topic of a number of analyst reports. Oppenheimer raised their target price on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, November 25th. Goldman Sachs Group upped their price target on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. William Blair upgraded shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. BidaskClub raised shares of Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 30th. Finally, Zacks Investment Research downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $69.54.
Shares of NASDAQ:CRSP traded up $1.66 during trading on Wednesday, reaching $72.37. The stock had a trading volume of 892,934 shares, compared to its average volume of 703,877. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The stock has a market cap of $4.00 billion, a P/E ratio of -21.04 and a beta of 3.30. The business has a fifty day moving average price of $54.81 and a 200-day moving average price of $47.38. Crispr Therapeutics has a fifty-two week low of $22.22 and a fifty-two week high of $74.00.
In related news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock valued at $3,620,760 in the last quarter. 21.40% of the stock is currently owned by corporate insiders.
A number of large investors have recently made changes to their positions in CRSP. Nikko Asset Management Americas Inc. increased its position in Crispr Therapeutics by 324.3% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock valued at $88,143,000 after buying an additional 1,430,364 shares in the last quarter. ARK Investment Management LLC grew its stake in Crispr Therapeutics by 34.7% in the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after buying an additional 701,332 shares in the last quarter. Orbimed Advisors LLC purchased a new position in Crispr Therapeutics in the 3rd quarter worth approximately $21,167,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after buying an additional 121,176 shares during the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after buying an additional 116,540 shares during the last quarter. 49.81% of the stock is currently owned by institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Stock Portfolio Tracker
For more information about research offerings from Zacks Investment Research, visit Zacks.com